WHODAS 2.0 in prodromal Huntington disease: measures of functioning in neuropsychiatric disease.

ABSTRACT: Clinical trials to improve day-to-day function in Huntington disease (HD) require accurate outcome measures. The DSM-5 recommends the World Health Organization Disability Assessment Schedule (WHODAS) 2.0 for use in neuropsychiatric disorders. The DSM-5 also states proxy measures may be useful when cognitive function may be impaired. We tested WHODAS participant and companion ratings for differences in baseline and longitudinal function in three prodromal HD groups and a control group. Participants with prodromal HD were stratified by disease progression (low, medium, and high disease burden) based on their cytosine-adenine-guanine (CAG)-age product (CAP) score. Participant (N=726) and companion (N=630) WHODAS scores were examined for group differences, and for participant versus companion

SUBMITTER: Downing NR 

PROVIDER: S-EPMC4350592 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature